Abivax Expands Trial for Potential Crohn’s Disease Treatment
Company Announcements

Abivax Expands Trial for Potential Crohn’s Disease Treatment

Abivax SA (FR:ABVX) has released an update.

Abivax SA has commenced a phase 2b clinical trial, ENHANCE-CD, to evaluate the efficacy and tolerance of its experimental drug, obefazimod, in treating moderately to severely active Crohn’s disease. The trial aims to provide a new oral, once-daily treatment option for patients who have not responded well to existing therapies. Positive phase 2 data from ulcerative colitis trials have already led to a phase 3 program for obefazimod, underscoring its potential in treating inflammatory bowel diseases.

For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskAbivax SA Ends Liquidity Contract, Reports Cash Balance
TheFlyAbivax data support potential of obefazimod as UC treatment option
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App